Pre-surgical oncolytic virotherapy improves breast cancer outcomes. (2nd November 2019)

• Record Type: Journal Article
• Authors: Mullins-Dansereau, Victor; Petrazzo, Grégory; Geoffroy, Karen; Béland, Delphine; Bourgeois-Daigneault, Marie-Claude
• Is Part Of: Oncoimmunology. Volume 8:Number 11(2019)
• Publication Date: 2019-11-02
• Subjects: Oncolytic virotherapy -- neoadjuvant therapy -- breast cancer -- triple-negative breast cancer -- immune checkpoint blockade; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1655363
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).